Immunosuppressive therapy. 1.
D000477:Alkylating Agents / Q000627:therapeutic use; D000744:Anemia, Hemolytic, Autoimmune / Q000188:drug therapy; D000906:Antibodies; D000963:Antimetabolites / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001379:Azathioprine / Q000627:therapeutic use; D001778:Blood Coagulation Disorders / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000188:drug therapy; D003424:Crohn Disease / Q000188:drug therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D003882:Dermatomyositis / Q000188:drug therapy; D005169:Factor VIII; D006505:Hepatitis / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011239:Prednisolone / Q000627:therapeutic use; D011696:Purpura, Thrombocytopenic / Q000188:drug therapy; D012595:Scleroderma, Systemic / Q000188:drug therapy
D000477:Alkylating Agents; D000906:Antibodies; D000963:Antimetabolites; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D005169:Factor VIII; D011239:Prednisolone; D015122:Mercaptopurine; D001379:Azathioprine; D008727:Methotrexate